Home › Cancer (all types) › Nebraska
Cancer (all types) clinical trials in Nebraska
22 studies for Cancer (all types) are looking for participants at sites in Nebraska.
Cities in Nebraska
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Nho - Revive Research Institute /ID# 277569, Lincoln
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07155187A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- Mary Lanning Healthcare ( Site 0019), Hastings
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06979596A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Nebraska Medicine, Omaha
- Nebraska Medicine - Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06989437A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- University of Nebraska Medical Center, Omaha
- Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06901531TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Nebraska Medical Center, Omaha
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University Of Nebraska Medical Center, Omaha
RecruitingPhase 2/3
All ages · All sexes · Updated Sep 18, 2026 · NCT03435796RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Nebraska Medical Center, Omaha
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT07002034Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07660055Project: Every Child for Younger Patients With Cancer
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Nebraska Medicine-Bellevue, Bellevue
- CHI Health Saint Francis, Grand Island
- Fred and Pamela Buffett Cancer Center - Kearney, Kearney
- and 8 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Nebraska Cancer Specialists, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 29, 2026 · NCT04198766A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- NHO Revive Research Institute, LLC /ID# 267869, Lincoln
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 282497, Omaha
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05650632Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Nebraska Cancer Specialist, Grand Island
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT06162221Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha
Recruiting
Ages 18 to 75 · All sexes · Updated Jun 17, 2026 · NCT05486572A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Nho - Revive Research Institute /ID# 276115, Lincoln
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT07005102CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Fred and Pamela Buffett Cancer Center, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078GEMINI-NSCLC: NSCLC Biomarker Study
- Nebraska Cancer Specialists, Omaha
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 5, 2026 · NCT05236114SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- University of Nebraska Medical Center, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 18, 2025 · NCT05970497Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
- Nebraska Cancer Specialists, Omaha
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 6, 2025 · NCT05234177Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- Nebraska Medicine - Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medicine, Omaha
Recruiting
Ages 18 and older · All sexes · Updated Nov 27, 2024 · NCT03860883From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.